# Adaptive Radiotherapy for Safe Hypofractionation

Source: https://onco.cc/trials/nct07516210/  
OnCo record `nct07516210` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Centre hospitalier de l'Université de Montréal (CHUM), not yet recruiting.

## Summary

Adaptive Radiotherapy for Safe Hypofractionation is a phase 2, randomised interventional study registered as NCT07516210 by Centre hospitalier de l'Université de Montréal (CHUM), with a registry enrolment figure of 264 participants, started 2026-05 and due to reach its primary completion in 2030-05. Interventions recorded: Adaptive Hypofractionated Radiotherapy; Standard-of-care Radiotherapy. Conditions listed: Cancer; Endometrial Cancer; Prostate Cancer; Cervical Cancer; Rectal Cancers. Primary outcome: Physician-reported Grade 2+ toxicity. Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ART-Hypo
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07516210
- Phase: 2
- Setting: Adaptive Radiotherapy for Safe Hypofractionation (ART-Hypo): A Bayesian Registry-Based Randomized Controlled Trial
- Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
- Enrolled: 264

## Sources

- ClinicalTrials.gov NCT07516210: https://clinicaltrials.gov/study/NCT07516210

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07516210.json